ReviewDrug design, development and therapy2022

Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment.

Dehua Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.